← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Translational Sciences, Inc.
Paradise Valley, AZ
$18,112,447
Total funding
10
Grants
Funding over time
peak $3.1M · FY2010–23$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$18,112,447 · 10
By mechanism
R44$12,438,024 · 5
U44$3,299,979 · 1
R42$1,519,440 · 1
R41$503,885 · 2
R43$351,119 · 1
Investigators at Translational Sciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke$1,713,006
R44 · FY2021 · NS
Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke$1,646,140
R44 · FY2020 · NS
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial$1,408,991
R44 · FY2021 · HL
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial$1,408,690
R44 · FY2022 · HL
HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II$1,321,017
R44 · FY2019 · HL
Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke$1,283,035
R44 · FY2023 · HL
Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke$1,161,162
R44 · FY2022 · HL
HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II$1,067,767
R44 · FY2020 · HL
Novel Methods for Dissolving Blood Clots$1,000,000
R44 · FY2015 · HL
Reducing Stroke by a Novel, Clot-dissolving Antibody$999,993
U44 · FY2012 · NS
Reducing Stroke by a Novel, Clot-dissolving Antibody$999,993
U44 · FY2014 · NS
Reducing Stroke by a Novel, Clot-dissolving Antibody$999,993
U44 · FY2013 · NS
Novel Methods for Dissolving Blood Clots$784,036
R42 · FY2012 · HL
Novel Methods for Dissolving Blood Clots$735,404
R42 · FY2013 · HL
HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II$423,216
R44 · FY2018 · HL
HLS Potent, novel inhibitor of fibrinolytic hemorrhage$351,119
R43 · FY2017 · HL
Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke$336,200
R41 · FY2019 · HL
Reducing Stroke by a Novel, Clot-dissolving Antibody$300,000
U44 · FY2011 · NS
Novel Methods for Dissolving Blood Clots$167,685
R41 · FY2010 · HL
Novel Methods for Dissolving Blood Clots$5,000
R44 · FY2015 · HL